Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant promise » significant rise (Expand Search), significant progress (Expand Search), significant positive (Expand Search)
promise decrease » point decrease (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant promise » significant rise (Expand Search), significant progress (Expand Search), significant positive (Expand Search)
promise decrease » point decrease (Expand Search)
-
861
-
862
Pan-cancer analyses of ANGPTL4 expression and its prognostic significance in the TCGA database.
Published 2025Subjects: -
863
Pan-cancer analyses of NFKB2 expression and its prognostic significance in the TCGA database.
Published 2025Subjects: -
864
-
865
-
866
-
867
Shares of antibiotic substances on total prescription in UTI treatment (N39.0, N30.0) by sex and age group in 2019 (female: n = 238.670 prescriptions; male: n = 40.641 prescription...
Published 2024Subjects: “…fluoroquinolone shares decreased…”
-
868
Shares of antibiotic substances on total prescription by quarter from 2013 to 2019 for female and male patients with UTI (N39.0, N30.0)(female: n = 1.681.255 prescriptions; male: n...
Published 2024Subjects: “…fluoroquinolone shares decreased…”
-
869
Shares of specialist groups prescribing 1<sup>st</sup>, 2<sup>nd</sup>, and 3<sup>rd</sup> antibiotic prescriptions in UTI treatment of females (N39.0, N30.0) in 2018 and 2019.
Published 2024Subjects: “…fluoroquinolone shares decreased…”
-
870
Number of antibiotic prescriptions in female and male patients with UTI (N30.0 and/or N39.0).
Published 2024Subjects: “…fluoroquinolone shares decreased…”
-
871
Shares of antibiotic substances on total prescription in female patients with UTI (N39.0, N30.0) by physician specialties (GPs: n = 1.299.641 prescriptions; gynecologists n = 141.8...
Published 2024Subjects: “…fluoroquinolone shares decreased…”
-
872
Comparison of 1<sup>st</sup>, 2<sup>nd</sup>, and 3<sup>rd</sup> antibiotic prescription.
Published 2024Subjects: “…fluoroquinolone shares decreased…”
-
873
UTI diagnoses by sex and physician specialty (2013–2019).
Published 2024Subjects: “…fluoroquinolone shares decreased…”
-
874
Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
875
Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
876
Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
877
Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
878
Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
879
Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
880
Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”